Which patients are offered and start prescription medicines for obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter observational project with a cross-sectional phase that records characteristics of all patients who are offered drug therapy for overweight or obesity and a prospective phase that follows patients who choose to start treatment. Data collected will include medical history, social and behavioral factors, clinical and laboratory measurements, and treatment tolerance. Patients aged 12 years and older who have an indication for approved anti-obesity drugs are eligible, while those with type 1 or type 2 diabetes or secondary forms of obesity are excluded. Those who start medication will be followed regularly for up to five years after treatment start or for 12 months after stopping therapy to monitor effectiveness, safety, and adherence in real-world care.

Why it matters

Who can join: the full rules

Inclusion Criteria: Age ≥ 12 years

* Therapeutic indication for taking one of the following drugs for the treatment of obesity: Orlistat, Naltrexone/Bupropion (Mysimba®), Liraglutide (Saxenda®), Semaglutide (Wegovy®), Tirzepatide (Mounjaro®)

Exclusion Criteria: - Type 1 and type 2 diabetes mellitus

\- Secondary forms of obesity:

* Hypothalamic obesity (both monogenic and acquired forms);
* Syndromic obesity (e.g., Prader-Willi, Alstrom, Bardet Biedl, etc.);
* Endocrinopathies associated with obesity (Cushing's syndrome, uncompensated hypothyroidism)

Where it's running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna
  Bologna, Bologna, Italy Recruiting

Study contacts

• Principal investigator: Uberto Pagotto, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Study coordinator: Uberto Pagotto, MD
• Email: uberto.pagotto@unibo.it
• Phone: 0512144190

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How incretin treatments affect muscle mass and function in people with overweight or obesity

  This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.

  Recruiting Radboud University Medical Center · Amsterdam and 1 other locations · NCT07929831

• Dose find for remimazolam plus alfentanil for gastroscopy in obese adults

  This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07925684

• Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults

  This study compares how much weight adults lose over two years when starting GLP-1 medicines versus adults who had sleeve gastrectomy at the same center.

  Recruiting Yuzuncu Yil University · Van · NCT07901777

• Gut barrier and inflammation after fast-food overfeeding in adults

  This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.

  Recruiting University Hospital, Gentofte, Copenhagen · Hellerup · NCT07893743

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• GLP-1 weight‑loss medicine: finding who will benefit most

  This study tests whether a GLP-1 drug called semaglutide helps with weight loss by changing eating behavior, to see which people it helps the most.

  Recruiting Phase 4 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07870538

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.